Innate Pharma S.A. IPHA
Set alert
1.40 USD -0.06 -4.11%
At close
1.34 -0.06 -4.29%
Pre-market · Nov 3, 7:14 AM ET
1.38 Day range 1.44
1.17 52-week range 2.71
- YTD
- -20.00%
- 1 year
- -28.93%
- Open
- 1.44
- Prev close
- 1.46
- Mkt cap
- 156.38M
- Vol
- 32.77K
- Avg vol
- 159.13K
- EPS
- -0.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.38
- High
- 1.44
- Forward P/E
- 4.67
- Beta
- 0.87
- Short ratio
- 5.63
- Inst. own
- 0.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 21, 2024
- 50-d avg
- 1.82
- 200-d avg
- 2.23
- 1y target
- 7.41
1M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
Analyst view
Consensus: buy
Buy
Price target (mean) 7.41 +429.4% upside
Now 1.40
- Target (low)
- 2.56
- Target (mean)
- 7.41
- Target (high)
- 11.50
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 53.68M | -12.9% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 85.66M | +59.6% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 15, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 18, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 16, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 24, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 15, 2022 | SVB Leerink | Maintained | — | Outperform |
| Sep 16, 2022 | Citigroup | Maintained | — | Buy |
| Aug 2, 2022 | SVB Leerink | Maintained | — | Outperform |
| May 11, 2022 | SVB Leerink | Maintained | — | Outperform |
| Sep 17, 2021 | SVB Leerink | Maintained | — | Outperform |
| Sep 3, 2021 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Sep 2, 2021 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Mar 19, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Dec 15, 2020 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Dec 14, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 24, 2020 | Goldman Sachs | Initiated | — | Neutral |
| Sep 9, 2020 | SVB Leerink | Maintained | — | Outperform |
| May 14, 2020 | SVB Leerink | Maintained | — | Outperform |